Kyle Registre's childhood dream of becoming a pilot can finally come true now that he says he's been cured of sickle cell complications.

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

Penn State Cancer Institute in Hershey has again earned international reaccreditation for stem cell transplantation.

Our fundamental challenge is not simply to create the data. Rather, it is to collect and analyze it systematically. Doing so ...

Sickle cell anaemia is a genetic blood disorder characterised by the production of an abnormal haemoglobin, known as haemoglobin S. Sickle cell disease changes the shape of blood cells into a crescent ...